<i>In Vitro</i> Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir is a research paper published in Journal of Clinical Microbiology (2019). On theSindex it has a DataRank of 1.1. It has been cited 14 times, with 13 citing works in its 1-hop citation network.
Voxilaprevir is a direct-acting antiviral agent (DAA) that targets the NS3/4A protease of hepatitis C virus (HCV). High sequence diversity of HCV and inadequate drug exposure during unsuccessful treatment may lead to the accumulation of variants with reduced susceptibility to DAAs, including NS3/4A protease inhibitors such as voxilaprevir.
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Base Score Contribution
0.406
From this paper's citation signal
Citation Network Contribution
0.661
From 11 citing papers with measurable signal
Ranked by citation count — the same ordering the engine uses when summing log1p(Cq) over citers.
DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 38% comes from its base citations and 62% from the citation network (11 citing papers contributed measurable signal).
Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.
Click a node to highlight its connections. Use scroll to zoom. Drag to pan.